Biocartis
PrivateLast Round
Debt
Nov 22, 2023
Est. Valuation
$490.7M
Total Funding Raised
$344.48M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Biocartis is a molecular diagnostics company that provides a fully automated, sample-to-result, real-time PCR platform for oncology and infectious disease testing.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Precision Medicine, Biotech Equipment
Business Model
B2B
Customer Profile
Usage-Based SaaS, Hardware Sales, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Biocartis Comparables
Compare Biocartis with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Hologic, Inc. | 79% | |
| Seegene Inc. | 77% | |
| Danaher Corporation | 74% |
Biocartis Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Debt | Nov 22, 2023 | ||||
| Recap | Nov 22, 2023 | ||||
| Private Placement | Nov 29, 2022 | ||||
| Private Placement | Jan 23, 2019 | ||||
| IPO | Apr 27, 2015 | ||||
Private Placement | Sep 4, 2014 |
Key People
Founding team and executive leadership
Biocartis Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| UBS Group AG | IPO |
| Korys | Series C, Series D |
| KBC Group N.V. | Debt |
| Advent Venture Partners | Series A, Series B |
| KBC Securities | Private Placement |
| Aescap | Series B |
| PMV | Private Placement, Series C, Series D |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors increased 44% MoM.
- Mar 24, 2026
Developing a rapid breast cancer gene signature test with Medical College of Wisconsin.
Recent news
Latest coverage and updates
- is_developingJul 7, 2026
Biocartis Group is developing precision oncology solutions on Jul 7th '26.
- partners_withJul 7, 2026
Biocartis partnered with Discovery Life Sciences on Jul 7th '26.
Biocartis Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Biocartis's valuation, stock price, and market status.
Is Biocartis a public or private company?
Biocartis is a private company.
What is the current stock price of Biocartis?
Biocartis is a private company with no public stock price. No recent secondary market data is available.
How much is Biocartis worth (valuation)?
Biocartis's valuation is estimated at $490.7M based on funding round data.
Can I buy Biocartis stock?
Biocartis shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Biocartis's last funding round?
Biocartis's most recent funding round was Recap on April 27, 2015.
Who are the main investors in Biocartis?
Key investors in Biocartis include KBC Securities, Aescap, PMV, Aescap Venture.
Will Biocartis IPO soon?
No public IPO plans have been announced for Biocartis.
How can I track Biocartis secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Biocartis's secondary market activity and sign up for updates.